ClinicalTrials.gov
public full text
Public Domain
A Placebo-Controlled, Phase 3 Study of Relugolix (TAK-385) 40 mg in the Treatment of Pain Symptoms Associated With Uterine Fibroids
The purpose of this study is to evaluate the efficacy and safety of Relugolix (TAK-385) in patients having pain symptoms associated with uterine fibroids.
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- Effects of 2-Aticyto Complex and D-Ribose on Pain and Clinical Course in Patients With Fibromyalgia#842857
- Predictors of pain improvement with Kampo formulas after UPOINT-guided management in chronic pelvic pain syndrome: a retrospective cohort study.#685644
- Open Label Extension Study of [S,S]-Reboxetine in Patients With Fibromyalgia#892158
- Long-term Use of Mifepristone in the Treatment of Adenomyosis#813223
- Loss of RESponse to Ustekinumab Treated by Dose Escalation#874377
Record · ID 1087346
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive